Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Receivables: 2020-2023

Historic Receivables for Revolution Medicines (RVMD) over the last 3 years, with Dec 2023 value amounting to $1.3 million.

  • Revolution Medicines' Receivables fell 73.16% to $1.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $8.1 million, marking a year-over-year decrease of 60.87%. This contributed to the annual value of $1.3 million for FY2023, which is 73.16% down from last year.
  • Latest data reveals that Revolution Medicines reported Receivables of $1.3 million as of Q4 2023, which was up 305.83% from $309,000 recorded in Q3 2023.
  • Over the past 5 years, Revolution Medicines' Receivables peaked at $12.8 million during Q4 2020, and registered a low of $309,000 during Q3 2023.
  • For the 3-year period, Revolution Medicines' Receivables averaged around $4.7 million, with its median value being $5.2 million (2022).
  • Data for Revolution Medicines' Receivables shows a maximum YoY tumbled of 93.74% (in 2023) over the last 5 years.
  • Revolution Medicines' Receivables (Quarterly) stood at $12.8 million in 2020, then crashed by 53.63% to $5.9 million in 2021, then decreased by 21.18% to $4.7 million in 2022, then crashed by 73.16% to $1.3 million in 2023.
  • Its last three reported values are $1.3 million in Q4 2023, $309,000 for Q3 2023, and $2.5 million during Q2 2023.